A Boston company that was the first to launch human mRNA vaccine testing in March to look for side effects also announced that it wants to apply to the US Food and Drug Administration (FDA) to allow it to be used in an emergency .
–
About 30,000 volunteers in the United States participated in the third phase of clinical trials. Half of them received the developed vaccine, half placebo. Covidem-19 infected 95 subjects, but only five received a new vaccine, the rest received a placebo. Eleven participants in the clinical trials had a serious course, but none of those who received the vaccine.
–
“The overall efficiency has been remarkable. It’s a big day, “Tal Zaks, chief health officer at Moderna, told the BBC. However, it is not yet clear how long the vaccine will protect the vaccinated, although Zaks said it “does not appear to lose its effectiveness.”
–
Interim data also do not show how well it protects older people. It is not yet clear whether the substance only blocks the threat of a serious course of the disease or also prevents its spread.
–
The Moderna vaccine will be easier to transport and distribute because it is stored at minus twenty degrees, while the Pfizer / BioNTech vaccine is at minus 75. Many medical facilities are not prepared for this.
–
According to the manufacturer, about a billion doses should be available next year. In the first phase, it is about 20 million for the USA.
–
As with Pfizer, it is also an mRNA vaccine that uses part of the RNA strand of the virus. It is coated with fat and can penetrate the cell, which then begins to form a protein with which the virus attacks the cells. T-lymphocytes react to the discovery of the protein and start destroying it. They also fight the virus.
—
